- Home
- ISRG vs AZN Comparison
ISRG vs AZN Comparison
Compare ISRG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRG
- AZN
- Stock Information
- Founded
- ISRG 1995
- AZN 1992
- Country
- ISRG United States
- AZN United Kingdom
- Employees
- ISRG N/A
- AZN N/A
- Industry
- ISRG Medical/Dental Instruments
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- ISRG Health Care
- AZN Health Care
- Exchange
- ISRG Nasdaq
- AZN Nasdaq
- Market Cap
- ISRG 200.0B
- AZN 228.9B
- IPO Year
- ISRG 2000
- AZN 1993
- Fundamental
- Price
- ISRG $538.59
- AZN $69.88
- Analyst Decision
- ISRG Buy
- AZN Strong Buy
- Analyst Count
- ISRG 18
- AZN 3
- Target Price
- ISRG $583.47
- AZN $95.00
- AVG Volume (30 Days)
- ISRG 1.8M
- AZN 3.7M
- Earning Date
- ISRG 07-17-2025
- AZN 07-24-2025
- Dividend Yield
- ISRG N/A
- AZN 2.17%
- EPS Growth
- ISRG 23.31
- AZN 22.71
- EPS
- ISRG 6.83
- AZN 4.97
- Revenue
- ISRG $8,714,900,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- ISRG $17.89
- AZN $9.56
- Revenue Next Year
- ISRG $15.14
- AZN $6.09
- P/E Ratio
- ISRG $79.66
- AZN $14.07
- Revenue Growth
- ISRG 19.08
- AZN 15.48
- 52 Week Low
- ISRG $413.82
- AZN $61.24
- 52 Week High
- ISRG $616.00
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- ISRG 55.97
- AZN 43.21
- Support Level
- ISRG $503.18
- AZN $69.65
- Resistance Level
- ISRG $544.24
- AZN $70.37
- Average True Range (ATR)
- ISRG 10.09
- AZN 0.96
- MACD
- ISRG 1.57
- AZN -0.41
- Stochastic Oscillator
- ISRG 87.13
- AZN 7.87
About ISRG Intuitive Surgical Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.